In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET.

在过去的两年中，晚期EGFR突变型非小细胞肺癌的治疗取得了实质性进展。最近的研究表明，第三代酪氨酸激酶抑制剂与化疗或靶向EGFR和MET的双特异性抗体的组合具有额外的益处。

Herein, we summarize these advances and their implications for clinical practice..

在此，我们总结了这些进展及其对临床实践的影响。。

Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springerlink上购买即时访问完整文章PDFBuy now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesSharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169–181 (2007).Article

参考文献Harma，S.V.，Bell，D.W.，Settleman，J。＆Haber，D.A。肺癌中的表皮生长因子受体突变。《国家癌症评论》7169-181（2007）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Morgillo, F., Della Corte, C. M., Fasano, M. & Ciardiello, F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open 1, e000060 (2016).Article

Morgillo，F.，Della Corte，C.M.，Fasano，M。＆Ciardiello，F。对EGFR靶向药物的耐药机制：肺癌。ESMO公开赛1，e000060（2016）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046–1061 (2014).Article

Cross，D.A.等人AZD9291是一种不可逆的EGFR TKI，克服了T790M介导的肺癌对EGFR抑制剂的耐药性。癌症发现。41046-1061（2014）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41–50 (2020).Article

Ramalingam，S.S.等人。未经治疗的EGFR突变晚期NSCLC中使用osimertinib的总生存率。N、 英语。J、 医学382,41-50（2020）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Nieva, J., Reckamp, K. L., Potter, D., Taylor, A. & Sun, P. Retrospective analysis of real-world management of EGFR-mutated advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and survival data. Drugs Real World Outcomes 9, 333–345 (2022).Article

Nieva，J.，Reckamp，K.L.，Potter，D.，Taylor，A。＆Sun，P。回顾性分析一线EGFR-TKI治疗后EGFR突变晚期NSCLC的现实管理：美国治疗模式，磨损和生存数据。药物现实世界结果9333-345（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Cho, B. C. et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2403614 (2024).Article

Cho，B.C.等人，Amivantamab加lazertinib治疗先前未经治疗的EGFR突变晚期NSCLC。N、 英语。J、 医学。https://doi.org/10.1056/NEJMoa2403614（2024年）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Felip, E. et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann. Oncol. https://doi.org/10.1016/j.annonc.2024.05.541 (2024).Article

Felip，E。等人。阿米万塔单抗联合拉泽替尼与奥西替尼治疗一线EGFR突变晚期非小细胞肺癌伴高危疾病生物标志物：MARIPOSA的二次分析。安科。https://doi.org/10.1016/j.annonc.2024.05.541（2024年）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935–1948 (2023).Article

Planchard，D。等人在EGFR突变的晚期NSCLC中使用或不使用化疗的Osimertinib。N、 英语。J、 医学3891935-1948（2023）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Passaro, A. et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann. Oncol. 35, 77–90 (2024).Article

Passaro，A。等人。在osimertinib疾病进展后，在EGFR突变的晚期NSCLC中，阿米万塔单抗联合化疗联合或不联合拉泽替尼：III期MARIPOSA-2研究的主要结果。安科。35，77-90（2024）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Passaro, A., Jänne, P. A., Mok, T. & Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer 2, 377–391 (2021).Article

。《自然癌症》2377-391（2021）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USAFatemeh Ardeshir-Larijani & Suresh S. RamalingamAuthorsFatemeh Ardeshir-LarijaniView author publicationsYou can also search for this author in.

下载参考文献作者信息作者和所属机构美国佐治亚州亚特兰大温希普癌症研究所埃默里大学医学院血液学和医学肿瘤学系Fatemeh Ardeshir Larijani＆Suresh S.RamalingamAuthorsFatemeh Ardeshir LarijaniView作者出版物您也可以在中搜索这位作者。

PubMed Google ScholarSuresh S. RamalingamView author publicationsYou can also search for this author in

PubMed Google ScholarSuresh S.RamalingamView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Suresh S. Ramalingam.Ethics declarations

Suresh S.Ramalingam。道德宣言

Competing interests

相互竞争的利益

S.S.R. has received institutional research grants for clinical trials support from Amgen, AstraZeneca, Bristol Myers Squibb, Merck and Pfizer. F.A.-L. declares no competing interests.

S、 。F、 洛杉矶宣布没有利益冲突。

Rights and permissionsReprints and permissionsAbout this articleCite this articleArdeshir-Larijani, F., Ramalingam, S.S. The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC.

。

Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00938-3Download citationPublished: 19 August 2024DOI: https://doi.org/10.1038/s41571-024-00938-3Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Clin Oncol（2024）。https://doi.org/10.1038/s41571-024-00938-3Download引文发布日期：2024年8月19日OI：https://doi.org/10.1038/s41571-024-00938-3Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供